PharmaCyte Biotech replaces CBIZ with Grassi as auditor
PMCB•PharmaCyte Biotech replaced CBIZ CPAs with Grassi as its independent auditor, effective October 14, 2026. Grassi will audit the fiscal year ending April 30, 2027; previously disclosed material weaknesses involved segregation of the CFO’s duties and management review controls.
1. Auditor change
PharmaCyte Biotech replaced CBIZ CPAs with Grassi as its independent auditor, effective October 14, 2026. Grassi will audit the fiscal year ending April 30, 2027, and begin interim reviews with the quarter ending October 31, 2026.
2. Prior audit disclosures
CBIZ’s audit reports for the fiscal years ended April 30, 2026 and 2025 contained no adverse opinions, disclaimers or qualifications. The company reported no accounting or auditing disagreements during those years or the interim period through October 14, 2026. Previously disclosed material weaknesses involved insufficient segregation of the CFO’s duties and inadequate management review controls.
